HOX genes promote cell proliferation and are potential therapeutic targets in adrenocortical tumours.

British Journal of Cancer
Jeffrey C FrancisAmanda Swain

Abstract

Understanding the pathways that drive adrenocortical carcinoma (ACC) is essential to the development of more effective therapies. This study investigates the role of the transcription factor HOXB9 and other HOX factors in ACC and its treatment. We used transgenic mouse models to determine the role of Hoxb9 in adrenal tumour development. Patient transcriptomic data was analysed for the expression of HOX genes and their association with disease. Drug response studies on various adrenocortical models were done to establish novel therapeutic options. Our human ACC dataset analyses showed high expression of HOXB9, and other HOX factors, are associated with poorer prognosis. Transgenic overexpression of Hoxb9 in the adrenal cortex of mice with activated Ctnnb1 led to larger adrenal tumours. This phenotype was preferentially observed in male mice and was characterised by more proliferating cells and an increase in the expression of cell cycle genes, including Ccne1. Adrenal tumour cells were found to be dependent on HOX function for survival and were sensitive to a specific peptide inhibitor. These studies show Hoxb9 can promote adrenal tumour progression in a sex-dependent manner and have identified HOX factors as potential drug targ...Continue Reading

References

Jun 7, 2002·Genes & Development·Deneen M WellikMario R Capecchi
Jan 18, 2003·Endocrine Research·S E NevilleR T Gladwell
Nov 5, 2003·Genesis : the Journal of Genetics and Development·Catherine A SchnabelMichael L Cleary
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Mar 23, 2006·The Journal of Clinical Endocrinology and Metabolism·Bruno Allolio, Martin Fassnacht
Jun 19, 2007·Cancer Research·Richard MorganHardev S Pandha
Oct 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jiangyong MiaoSandra Orsulic
Dec 7, 2007·Journal of Molecular Endocrinology·Edson F NogueiraWilliam E Rainey
Jul 25, 2009·Molecular Endocrinology·Mohamad ZubairKen-Ichirou Morohashi
Apr 2, 2010·Nature Reviews. Cancer·Nilay Shah, Saraswati Sukumar
Jan 10, 2013·World Journal of Urology·François AudenetMorgan Rouprêt
Jan 16, 2014·Endocrine Reviews·Tobias ElseGary D Hammer
Apr 22, 2014·Nature Genetics·Guillaume AssiéJérôme Bertherat
Dec 10, 2014·The Journal of Clinical Endocrinology and Metabolism·C Christofer JuhlinTobias Carling
Jun 18, 2016·Genes & Development·Valerie VidalAndreas Schedl
Aug 10, 2016·Cancer Cell·Siyuan ZhengRoel G W Verhaak
Apr 4, 2017·Oncogene·M Batisse-LignierA-M Lefrançois-Martinez
Apr 21, 2017·Oncotarget·Richard MorganHardev S Pandha
Jan 30, 2019·Genes & Development·Kaitlin J BashamGary D Hammer
May 21, 2019·Cell Stem Cell·Anaëlle GrabekAndreas Schedl

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq
transgenic
transgenics
sumoylation

Software Mentioned

STRING
Bioconductor package
Hmisc
TopHat RNA - seq
lsmeans
R package survival _
GSEA
HTSeq count
R
lmerTest

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.